Read about Endologix
in the news

Embrace the evidence.

The Latest:

Endologix Announces 36-Month Results of DETOUR2 Study at 2024 VIVA Late-Breaking Clinical Trial Session

See Release

All News

Archives

Endologix Announces 24-Month Results of DETOUR- 2 Study at 2023 Vascular Annual Meeting

Endologix receives FDA Approval of the DETOUR™ System to Treat Long Complex Superficial Femoropopliteal Lesions in Patients with PAD.

Endologix Announces 150th Patient Enrolled in JAGUAR Randomized Controlled Trial

Endologix Wins “Medical Device Engineering Breakthrough” Award in 7th Annual MedTech Breakthrough Awards Program

Five-Year Results of the LEOPARD Trial published in the Journal of Vascular Surgery (JVS)